$OCGN When the FDA "recommended" OCGN file for BLA, rather than issue an EUA, why didn't they raise question and file for EUA anyway? Furthermore, why would they not have immediately began phase 1 clinical trials in the US? They know it's a requirement to obtain a BLA. They would have phase 1 complete with data to submit for EUA right NOW, while continuing to seek BLA with phase 2 trials already underway. Does any of this make sense?